Impact of lipoprotein(a) levels and apolipoprotein(a) isoform size on risk of coronary heart disease

Observational and genetic studies have shown that lipoprotein(a) [Lp(a)] levels and apolipoprotein(a) [apo(a)] isoform size are both associated with coronary heart disease (CHD) risk, but the relative independence of these risk factors remains unclear. Clarification of this uncertainty is relevant to the potential of future Lp(a)‐lowering therapies for the prevention of CHD.

[1]  M. Landray,et al.  HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment , 2013, European heart journal.

[2]  F. Kronenberg,et al.  Lipoprotein(a): resurrected by genetics , 2013, Journal of internal medicine.

[3]  William Weintraub,et al.  Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. , 2011, The New England journal of medicine.

[4]  L. Cupples,et al.  Lipoprotein(a) levels, apo(a) isoform size, and coronary heart disease risk in the Framingham Offspring Study , 2011, Journal of Lipid Research.

[5]  Christopher P Cannon,et al.  Safety of anacetrapib in patients with or at high risk for coronary heart disease. , 2010, The New England journal of medicine.

[6]  J. Borén,et al.  Lipoprotein(a) as a cardiovascular risk factor: current status , 2010, European heart journal.

[7]  P. Ridker,et al.  Lipoprotein(a) and risk of type 2 diabetes. , 2010, Clinical chemistry.

[8]  J. Danesh,et al.  Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants. , 2010, Journal of the American College of Cardiology.

[9]  R. Collins,et al.  Genetic variants associated with Lp(a) lipoprotein level and coronary disease. , 2009, The New England journal of medicine.

[10]  K. Berg.  A NEW SERUM TYPE SYSTEM IN MAN--THE LP SYSTEM. , 2009, Acta pathologica et microbiologica Scandinavica.

[11]  Stephen Kaptoge,et al.  Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. , 2009, JAMA.

[12]  Børge G Nordestgaard,et al.  Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. , 2009, JAMA.

[13]  G. Utermann,et al.  Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events , 2009, Nature Clinical Practice Cardiovascular Medicine.

[14]  Benjamin J. Wright,et al.  Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease , 2009, Nature Genetics.

[15]  L. Carlson,et al.  Nicotinic acid: the broad‐spectrum lipid drug. A 50th anniversary review , 2005, Journal of internal medicine.

[16]  P. Skerrett,et al.  Physicians' Health Study , 2005 .

[17]  E. Brilakis,et al.  Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. , 2005, The New England journal of medicine.

[18]  R. Ramakrishnan,et al.  Lipoprotein(a): an elusive cardiovascular risk factor. , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[19]  P. Ridker,et al.  Apolipoprotein(a) size and lipoprotein(a) concentration and future risk of angina pectoris with evidence of severe coronary atherosclerosis in men: The Physicians' Health Study. , 2004, Clinical chemistry.

[20]  M. Koschinsky,et al.  Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions. , 2003, Clinical chemistry.

[21]  Christopher M Thomas,et al.  Apolipoprotein [a] genotype influences isoform dominance pattern differently in African Americans and Caucasians. , 2002, Journal of lipid research.

[22]  H. Hobbs,et al.  Relation between number of apolipoprotein(a) kringle 4 repeats and mobility of isoforms in agarose gel: basis for a standardized isoform nomenclature. , 1996, Clinical chemistry.

[23]  M. Farrer,et al.  Coronary artery disease is associated with increased lipoprotein(a) concentrations independent of the size of circulating apolipoprotein(a) isoforms. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[24]  E. Boerwinkle,et al.  Apo(a) isoforms predict risk for coronary heart disease. A study in six populations. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[25]  E. Boerwinkle,et al.  Apolipoprotein(a) phenotypes, Lp(a) concentration and plasma lipid levels in relation to coronary heart disease in a Chinese population: evidence for the role of the apo(a) gene in coronary heart disease. , 1992, The Journal of clinical investigation.

[26]  G. Utermann,et al.  The mysteries of lipoprotein(a). , 1989, Science.

[27]  R. Magno,et al.  Coronary heart disease , 1957 .

[28]  U. Nowak‐Göttl,et al.  Testing for apolipoprotein(a) phenotype using isoelectric focusing and immunoblotting technique. , 2013, Methods in molecular biology.

[29]  F. Kronenberg,et al.  Lipoprotein(a) in renal disease. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.